Clinical trials
Stomach Neoplasms trials in Chile
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 9 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Terminated | 5 |
| Active, not recruiting | 4 |
| Recruiting | 4 |
| Unknown status | 4 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pontificia Universidad Catolica de Chile | 6 |
| Merck Sharp & Dohme LLC | 5 |
| Bristol-Myers Squibb | 4 |
| Amgen | 3 |
| Fundación para la Investigación del Hospital Clínico de Valencia | 3 |
| Arcus Biosciences, Inc. | 2 |
| Daiichi Sankyo | 2 |
| Eli Lilly and Company | 2 |
| Jazz Pharmaceuticals | 2 |
| National Cancer Institute (NCI) | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stomach Neoplasms | 44 |
| Neoplasms | 7 |
| Adenocarcinoma | 5 |
| Colorectal Neoplasms | 4 |
| Esophageal Neoplasms | 4 |
| Carcinoma, Hepatocellular | 3 |
| Gastritis, Atrophic | 3 |
| Triple Negative Breast Neoplasms | 3 |
| Uterine Cervical Neoplasms | 3 |
| Biliary Tract Neoplasms | 2 |
Trials
Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.